NEW YORK, May 28 - Orchid Biosciences has appointed Paul Kelly as its new CEO, filling a position left vacant when Dale Pfost left in December 2002, the company announced today.
Kelly, 43, is an Australian-born endocrinologist and the former CEO of Gemini Genomics, which he co-founded in 1995. Gemini, a clinical genomics company that collected genetic, clinical, and environmental data from different human populations and analyzed this data to look for drug targets, merged with Sequenom in 2001.
Since leaving Gemini, Kelly founded Nanovis, a materials science company, and AgaMatrix, a medical devices company. He most recently held the CEO post at data analysis company OmniViz.
"We believe that Paul has the right mix of vision and hands-on expertise in the commercialization of clinical genetics, genoprofiling and research services for the biomedical and biotechnology sectors to take Orchid to its next stage of growth," said George Poste, chairman of Orchid, in a statement.